RESEARCH TRIANGLE PARK, N.C., Dec. 7, 2005 (PRIMEZONE) -- Enhance Biotech Inc. (Pink Sheets:EBOI), a Specialty Pharmaceutical company that acquires, develops and seeks to commercialize drugs primarily in the Lifestyle Drug market, today announced that it has received clearance from the FDA to proceed with Phase 1 clinical trials for its propriety selective delta agonist, DPI-221, for urge and mixed Urinary Incontinence (UI). This is a novel mechanism for the potential treatment of UI.
The Phase I clinical trial for DPI-221 is planned to begin early in 2006.
UI is a common illness, particularly in the growing elderly population. It is defined as the uncontrollable loss of urine from the bladder and is the primary cause of institutionalization of the elderly. The syndrome is comprised primarily of three subtypes: urge incontinence, stress incontinence and mixed incontinence. The target condition for our UI compound, DPI-221, is urge and mixed incontinence, in which the patient cannot control the emptying of the bladder appropriately after the recognition of the need to urinate. According to Decision Resources, there are approximately 15 million cases of significant urge and mixed UI in the U.S.
About Enhance Biotech, Inc.
Enhance is an emerging Specialty Pharmaceutical company that acquires, develops and seeks to commercialize drugs primarily in the "Lifestyle Drug" market. Lifestyle Drugs target chronic long-term conditions that are not necessarily life threatening, but can severely affect the quality of life. This is one of the fastest growing sectors in the pharmaceutical industry and Enhance Biotech is uniquely positioned to take full advantage of this opportunity. Our drug pipeline focuses on three major segments in the Lifestyle Drug market: Urology, CNS and Dermatology. Our most clinically advanced products include a drug to treat Premature Ejaculation that is currently in Phase 2 trials and a mixed delta/mu receptor compound for Moderate-to-Severe Pain that has completed Phase 1.
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Enhance Biotech's compounds under development in particular; the potential failure of Enhance Biotech's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Enhance Biotech' compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Enhance Biotech' business, structure or projections; the development of competing products; uncertainties related to Enhance Biotech' dependence on third parties and partners; and those risks described in the filings with the SEC. Enhance Biotech disclaims any obligation to update these forward-looking statements.